title: Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine.
abstract: OBJECTIVE
  The objectives of this study were to examine the whole-serum N-glycan profile of patients with unresectable pancreatic cancer and to evaluate the ability of glycans to predict gemcitabine treatment efficacy and patient survival.
  
  
  METHODS
  We collected serum from 52 patients with advanced pancreatic cancer before they began gemcitabine monotherapy. The serum glycan profile was measured through comprehensive quantitative high-throughput glycome analysis and compared with the treatment efficacy and patient survival.
  
  
  RESULTS
  Of the 61 glycans detected, the serum levels of glycan 4310 (molecular weight [m/z] 1549.566), 6301 (m/z 2032.724), and 9200 (m/z 2010.692) were high in patients with a short time to tumor progression (TTP). Multivariate analysis revealed that a high glycan 9200 concentration was an independent risk factor for shorter TTP (hazard ratio, 2.11; 95% confidence interval, 1.07-4.17) and poor overall survival (hazard ratio, 2.56; 95% confidence interval, 1.08-6.19). The median TTP of patients with up-regulation of 9200 after gemcitabine treatment was shorter than for the remaining patients (91 vs 301 days; P = 0.0005). A similar relationship was observed for overall survival (median, 181 vs 561 days; P = 0.001).
  
  
  CONCLUSIONS
  Glycan 9200 is a possible biomarker predicting gemcitabine efficacy survival in patients with unresectable pancreatic cancer.
authors: From the *Departments of Gastroenterology and Hepatology, and †Molecular Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama City, Okayama, Japan; ‡Ezose Sciences Inc, Pine Brook, NJ; §Field of Drug Discovery Research, Faculty of Advanced Life Science, Graduate School of Life Science, Hokkaido University; and ∥Medicinal Chemistry Pharmaceuticals, Co, Ltd, Sapporo, Hokkaido, Japan.
authors: Koji
authors: K
authors: Miyahara
authors: Kazuhiro
authors: K
authors: Nouso
authors: Yuki
authors: Y
authors: Morimoto
authors: Hideaki
authors: H
authors: Kinugasa
authors: Hironari
authors: H
authors: Kato
authors: Naoki
authors: N
authors: Yamamoto
authors: Koichiro
authors: K
authors: Tsutsumi
authors: Kenji
authors: K
authors: Kuwaki
authors: Hideki
authors: H
authors: Onishi
authors: Fusao
authors: F
authors: Ikeda
authors: Shinichiro
authors: S
authors: Nakamura
authors: Hidenori
authors: H
authors: Shiraha
authors: Akinobu
authors: A
authors: Takaki
authors: Taku
authors: T
authors: Nakahara
authors: Yoshiaki
authors: Y
authors: Miura
authors: Hidehisa
authors: H
authors: Asada
authors: Maho
authors: M
authors: Amano
authors: Shin-Ichiro
authors: S
authors: Nishimura
authors: Kazuhide
authors: K
authors: Yamamoto
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D021441:Carcinoma, Pancreatic Ductal / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006023:Glycoproteins / Q000097:blood*; D006031:Glycosylation; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D011134:Polysaccharides / Q000097:blood*; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D006023:Glycoproteins; D011134:Polysaccharides; D003841:Deoxycytidine; D000093542:Gemcitabine